About Phoremost ltd
PhoreMost Ltd: Expanding Druggable Space with SITESEEKER®
PhoreMost Ltd is a UK-based biopharmaceutical company that is revolutionizing the drug discovery process through its innovative SITESEEKER® platform. The company's mission is to expand the druggable space by identifying novel drug targets and developing new therapies for unmet medical needs.
The SITESEEKER® platform uses a unique approach called "PROTEINiD" to identify and validate potential drug targets. This approach involves screening millions of proteins in their native state, rather than using recombinant proteins or peptides, which can lead to false positives or negatives. By screening proteins in their natural conformation, PhoreMost can identify previously unknown protein-protein interactions that are essential for disease progression.
PhoreMost's proprietary technology has already yielded promising results in several therapeutic areas, including cancer, neurodegenerative diseases, and infectious diseases. In partnership with leading pharmaceutical companies and academic institutions, PhoreMost is discovering and developing new drugs that target these previously undruggable proteins.
One of the key advantages of the SITESEEKER® platform is its ability to identify targets that are specific to certain disease states or patient populations. This precision medicine approach allows for more personalized treatments that are tailored to individual patients' needs.
In addition to its drug discovery efforts, PhoreMost also offers contract research services through its subsidiary company Pherin Pharmaceuticals Ltd. These services include target identification and validation, hit-to-lead optimization, medicinal chemistry optimization, and preclinical development.
PhoreMost's team consists of experienced scientists with expertise in protein biochemistry, cell biology, pharmacology, medicinal chemistry, and drug development. The company has received funding from several sources including venture capital firms such as Morningside Ventures and Parkwalk Advisors as well as government grants from Innovate UK.
Overall Phoremost ltd represents an exciting opportunity for investors and partners looking to be at the forefront of drug discovery and development. With its innovative SITESEEKER® platform, precision medicine approach, and experienced team, PhoreMost is well-positioned to make a significant impact on the pharmaceutical industry and improve patient outcomes.